In a single-center retrospective analysis, approximately two-thirds of patients with treatment-refractory headache disorders reported improvement with off-label suzetrigine, supporting further prospective evaluation of the selective NaV1.8 inhibitor.
A new phase 2 trial, presented at AAIC 2026, aims to evaluate the effects of urolithin A on mitophagy/autophagy activity, oxidative stress, multi-omic profiling, and cognitive function in APOE4 carriers.
The approval allows patients to begin lecanemab treatment at home via weekly subcutaneous injection, eliminating the 18-month IV requirement that previously preceded any at-home dosing.
The APPLAUDS trial will evaluate mivelsiran, an intrathecally delivered siRNA targeting amyloid precursor protein, in cognitively stable adults aged 40 to 55 with early-stage Down syndrome and early-stage Alzheimer disease who have elevated amyloid burden.
In the largest study of its kind, researchers examined the potential neurological effects of repetitive head impacts in retired elite soccer players, with findings offering new insights into symptoms, brain structure, and future research directions. [WATCH TIME: 3 Minutes]
Post hoc analyses from the phase 3 GRADUATE program suggest higher baseline tau pathology may limit amyloid removal with gantenerumab, offering new insight into factors that could influence response to anti-amyloid therapy.
Leslie M. Thompson, PhD; Ravi Rajmohan, MD, and Jefferson W. Chen, MD, from UCI Health discuss the rationale, delivery, and early steps of REGEN4HD, the world's first neural stem cell phase 1b/2a clinical trial for Huntington disease.
In a prespecified analysis presented at AAIC 2026, findings showed that plasma p-tau217 declined from baseline in valiltramiprosate-treated MCI patients compared with placebo over 78 weeks.
Here's some of what is coming soon to NeurologyLive® this week.
In a cross-sectional analysis of more than 1700 participants, plasma CGRP concentrations did not distinguish individuals with migraine from healthy controls, suggesting limited utility as a standalone diagnostic biomarker.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is RNA-targeted therapeutics
The director of the Division of Neuroscience at IRCCS Istituto Ortopedico Rizzoli discusses why targeting shared biologic pathways, rather than individual mutations, may represent a promising therapeutic strategy for Charcot-Marie-Tooth disease. [WATCH TIME: 2 minutes]
An Oxford study found that current smokers with MOGAD had a 2.2-times higher annualized relapse rate than never smokers, whereas past smokers showed no elevated risk, supporting smoking cessation as a modifiable management target.
Neurology News Network for the week ending July 11th, 2026. [WATCH TIME: 4 minutes]
Ahead of the 2026 Alzheimer's Association International Conference, David Wolk, MD, discusses the meeting's biggest scientific themes, from plasma biomarkers and disease-modifying therapies to emerging technologies and evolving clinical practice.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 10, 2026.
Recent findings from a study of growth and nutritional status in primary ciliary dyskinesia revealed high rates of undernutrition, obesity, and vitamin D insufficiency across pediatric and adult populations.
Carol Rosen, MD, professor emerita of pediatrics at Case Western Reserve University School of Medicine, discussed the transformation of pediatric sleep medicine from a clinical curiosity to a core medical specialty at SLEEP 2026.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Daniel Ontaneda, MD, PhD. [LISTEN TIME: 20 minutes]
The first randomized, double-blind trial directly comparing the 2 anti-CD20 agents showed rituximab met the prespecified noninferiority criterion on MRI suppression, with a similar serious adverse event profile and a substantially lower cost.
AbobotulinumtoxinA met its primary end point in both the E-BEOND and C-BEOND phase 3 trials, marking the first time a botulinum toxin has demonstrated statistically significant efficacy in episodic migraine prevention.
Fariha Abbasi-Feinberg, MD, FAASM, FAAN, newly installed president of the American Academy of Sleep Medicine and medical director of sleep medicine at Millennium Physician Group, shares her clinical and policy priorities for the year ahead and her vision for the future of sleep medicine.
At CMSC 2026, the associate professor of neurology at the Medical College of Wisconsin discussed the need to reconsider clinical trial paradigms by recognizing the role of immune cells in MS. [WATCH TIME: 6 minutes]
Led by Na Tosha Gatson, MD, PhD, FAAN, director of the Center for Neuro-Oncology at the Indiana University Health Neurosciences and Cancer Institutes, this new column translates complex neuro-oncology topics into accessible, evidence-based insights.
TG Therapeutics has indicated it plans to submit a supplemental BLA to the FDA in the second half of 2026, seeking approval for the consolidated initiation regimen of ublituximab-xiiy.
At CMSC 2026, the director of the multiple sclerosis research unit at Ottawa Hospital discussed how integrating clinical research into MS practice enhances clinician expertise. [WATCH TIME: 5 minutes]
The professor of neurology and neuroscience at Johns Hopkins University School of Medicine discussed the ongoing debate around animal models in neuropathy research, the rise of iPSC-derived systems, and why he believes both approaches are needed going forward.
Cleveland Clinic pilots HAP-E, guiding older adults to manage epilepsy and cognitive decline with lifestyle tools, medication support, and virtual access.
Findings from a 25-year analysis showed that tiapride was associated with significantly fewer adverse effect–related discontinuations than tetrabenazine in patients with Huntington disease chorea.
A sleep specialist and sleep patient advocate discussed diagnostic and patient-reported outcome measures that aim to better capture the cognitive, functional, and psychosocial burden of central disorders of hypersomnolence.
